Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

Joseph Rubin, Jaffer Ajani, William Schirmer, Alan P. Venook, Ronald Bukowski, Rodney Pommier, Leonard Saltz, Paresh Dandona, Lowell Anthony

Producción científica: Article › revisión exhaustiva

370 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science